Not Signed In -
Methylphenidate |
Methylin; Ritalin |
Clinical Trial: Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
This study has been completed.
Purpose
The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Cocaine-Related Disorders Substance-Related Disorders | Drug: Methylphenidate | Phase IV |
MedlinePlus related topics: Cocaine Abuse; Drug Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Diagnostic, Double-Blind, Placebo Control
Official Title: Methylphenidate Raclopride PET test
Further Study Details:
The objective of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.
Eligibility
Ages Eligible for Study: 18 Years - 75 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Healthy normals
Exclusion Criteria:
History of head trauma or loss of consciousness. Significant medical history. History of seizures.
Location Information
New York
New York MDRU, New York, New York, 10010, United States
Study chairs or principal investigators
John Rotrosen, M.D., Principal Investigator, New York MDRU
More Information
Study ID Numbers: NIDA-5-0013-11; Y01-5-0013-11
Record last reviewed: December 2002
Last Updated: December 3, 2004
Record first received: April 18, 2001
ClinicalTrials.gov Identifier: NCT00015301
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: December 2002
Last Updated: December 3, 2004
Record first received: April 18, 2001
ClinicalTrials.gov Identifier: NCT00015301
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
